Evofem Biosciences, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported net income was USD 89.51 million compared to net loss of USD 74.06 million a year ago. Basic earnings per share from continuing operations was USD 136.25 compared to basic loss per share from continuing operations of USD 900 a year ago. Diluted loss per share from continuing operations was USD 5 compared to USD 900 a year ago.
For the nine months, net loss was USD 68.36 million compared to USD 153.64 million a year ago. Basic loss per share from continuing operations was USD 206.25 compared to USD 2,386.25 a year ago. Diluted loss per share from continuing operations was USD 206.25 compared to USD 2,386.25 a year ago.